Inhibrx Biosciences

Historical price data

Inhibrx Biosciences is a public, clinical-stage biotech focused on developing differentiated biologics for high-need oncology indications. Its core innovation is a versatile single-domain antibody (sdAb) platform that enables the creation of multi-valent, conditionally active molecules with potential advantages over conventional antibodies. The company's strategy centers on advancing its two lead clinical assets, a tetravalent DR5 agonist for sarcoma and a hexavalent OX40 agonist for solid tumors, while leveraging its lean, protein-engineering expertise to create future pipeline candidates.

Proprietary single-domain antibody (sdAb) platform enabling the engineering of multi-valent, conditionally active biologic therapeutics with superior tissue penetration and tailored mechanisms of action.

Faces competition in DR5 agonists from legacy failed programs and new modalities, and in OX40 from numerous big pharma and biotech candidates. Differentiates through its platform's ability to create conditionally active, multi-valent molecules designed for superior potency and safety.